RT @Thomas_Wilckens: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the ESMO Scale for Clinical Actionab…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
A framework to rank genomic alterations as targets for cancer #precisionmedicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/HLRSzvgD4A https://t.co/dA7bDRQ8tN
framework to rank #genomic alterations as targets for #cancer #precision #medicine: the ESMO Scale for Clinical Actionability of molecular Targets (#ESCAT) | Annals of Oncology | Oxford Academic https://t.co/8WlZHDsuBq
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/wtVoWWkOAv
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
a step forward to differentiate the signal from the noise
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @prat_aleix: will this eventually include RNA-based and protein-based biomarkers as well? or just dna-seq results? thanks and congrats!…
Adjusting physician and patient expectations to clinical reality is critical for maintaining trust in clinical research and providing the best care. https://t.co/1UzU1ch8nL
will this eventually include RNA-based and protein-based biomarkers as well? or just dna-seq results? thanks and congrats!
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
This paper gives a table of databases to check our variants of interest against for clinical significance....very useful!
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target prioritization and resistance markers will come soon @quimmateo @FAndreMD. Increased access to clinical trials needed. https://t.co/e
ESMO scale for clinical actionabity of molecular targets #ESCAT #Cancer #Genomics @Annals_Oncology https://t.co/XuoTSU7Qyc
@myESMO addresses the urgent need to systematicallt interpret molecular targets in #cancer #PrecisionMedicine
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
Fantastic & much needed! ESMO presents a framework to select patients for targeted therapies by ranking genomic alterations based on clinical actionability https://t.co/TIc1A64HcB Kudos to the team @CharlesSwanton @VanAllenLab @FAndreMD @myESMO @Annal
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
The ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) classification system provides a systematic framework to rank molecular targets based on clinical evidence of actionability: tier I, targets ready for implementation in routine clinical
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular targets (ESCAT). By @CharlesSwanton @FAndreMD @VanAllenLab Five tiers of evidence plus “X” (“as in don’t even think about it”) http
Not all mutations are pathogenic. Not all variants of the same genes exert a similar effect. Alteration-drug matches are not valid in all tumor types. Congratulations to the working group for a very important effort! #PrecisionMedicine
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
A real step in the right direction. I hope work is ongoing with the current #bigdata portals to begin to incorporate these type of scores. Would be great to have examples included in Table 2. What are the current plans for implementation? #ngs #PrecisionM
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
Link to article: A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/uCgwb8yhe5
Congrats @quimmateo and colleagues on this important work on harmonization for interpretation of NGS
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
Nice work @quimmateo and team!
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) online now https://t.co/BbmCMQKhEG @FAndreMD @quimmateo @CharlesSwanton @rdienstmann
Informative Annals of Oncology open access article, A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/HfbvUy9Gr
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…